The periurethral injection of polytetrafluoroethylene in the treatment of stress urinary incontinence is a therapeutic option introduced more than 30 years ago which is considered rapid, effective and burdened with low complications. This particular therapeutic option when utilized for the treatment of post-prostatectomy incontinence, presents some problems due to the oncologic follow-up of these patients with particular regard to the presence of local recurrences. In fact these injections should not interfere with the standard methods of evaluation of the urethro-vescical anastomosis (DRE and TRUS). The polytetrafluoroethylene in our experience does not accomplish with these requirements because it modifies the palpatory and sonographic findings hindering a reliable evaluation of that region.